PARP inhibition is synthetic lethal with deleterious BRCA1 and BRCA2 mutations because homologous recombination repair (HRR) cannot restore these double-strand breaks, introducing genome instability by nonhomologous end joining or leading to tumor cell death (13). Here, BRCA2 is linked to neoplasm.